Advances in Chronic Kidney Disease
Volume 12, Issue 4 , Pages 385-396 , October 2005

Anemia in Children with Chronic Kidney Disease

  • Larry A. Greenbaum

      Affiliations

    • Corresponding Author InformationAddress correspondence to Larry A. Greenbaum, MD, PhD, Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226

References 

  1. McGonigle RJ , Boineau FG , Beckman B , et al.   Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease . J Lab Clin Med . 1985;105:449–458
  2. Muller-Wiefel DE , Sinn H , Gilli G , et al.   Hemolysis and blood loss in children with chronic renal failure . Clin Nephrol . 1977;8:481–486
  3. National Kidney Foundation . NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease . Am J Kidney Dis . 2001;37:S182–S238
  4. Eknoyan G , Latos D , Lindberg J . Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder National Kidney Foundation Carnitine Consensus Conference . Am J Kidney Dis . 2003;41:868–876
  5. Polenakovic M , Sikole A . Is erythropoietin a survival factor for red blood cells? . J Am Soc Nephrol . 1996;7:1178–1182
  6. Richardson D , Lindley E , Bartlett C , et al.   A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response . Am J Kidney Dis . 2003;42:551–560
  7. Frankenfield DL , Neu AM , Warady BA , et al.   Anemia in pediatric hemodialysis patients (Results from the 2001 ESRD Clinical Performance Measures Project) . Kidney Int . 2003;64:1120–1124
  8. Kalantar-Zadeh K , Ikizler TA , Block G , et al.   Malnutrition-inflammation complex syndrome in dialysis patients (Causes and consequences) . Am J Kidney Dis . 2003;42:864–881
  9. Barany P , Divino Filho JC , Bergstrom J . High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients . Am J Kidney Dis . 1997;29:565–568
  10. Barany P . Inflammation, serum C-reactive protein, and erythropoietin resistance . Nephrol Dial Transplant . 2001;16:224–227
  11. Rao DS , Shih MS , Mohini R . Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia . N Engl J Med . 1993;328:171–175
  12. Pronai W , Riegler-Keil M , Silberbauer K , et al.   Folic acid supplementation improves erythropoietin response . Nephron . 1995;71:395–400
  13. Kaiser L , Schwartz KA . Aluminum-induced anemia . Am J Kidney Dis . 1985;6:348–352
  14. Berard E , Iordache A . Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children (About two cases) . Nephron . 1992;62:368–369
  15. Erturk S , Nergizoglu G , Ates K , et al.   The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients . Nephrol Dial Transplant . 1999;14:1912–1916
  16. Chavers BM , Roberts TL , Herzog CA , et al.   Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients . Kidney Int . 2004;65:266–273
  17. Centers for Medicare & Medicaid Services (2002 annual report, end stage renal disease clinical performance measures project) . Am J Kidney Dis . 2003;42:S1–S96
  18. Fadrowski JJ , Furth SL , Fivush BA . Anemia in pediatric dialysis patients in end-stage renal disease network 5 . Pediatr Nephrol . 2004;19:1029–1034
  19. Foley RN , Parfrey PS , Morgan J , et al.   Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy . Kidney Int . 2000;58:1325–1335
  20. Evans RW , Rader B , Manninen DL . The quality of life of hemodialysis recipients treated with recombinant human erythropoietin (Cooperative Multicenter EPO Clinical Trial Group) . JAMA . 1990;263:825–830
  21. Revicki DA , Brown RE , Feeny DH , et al.   Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients . Am J Kidney Dis . 1995;25:548–554
  22. Canadian Erythropoietin Study Group . Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis . BMJ . 1990;300:573–578
  23. Frank H , Heusser K , Hoffken B , et al.   Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients . Kidney Int . 2004;66:832–840
  24. Locatelli F , Pisoni RL , Combe C , et al.   Anaemia in haemodialysis patients of five European countries (association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)) . Nephrol Dial Transplant . 2004;19:121–132
  25. Gouva C , Nikolopoulos P , Ioannidis JP , et al.   Treating anemia early in renal failure patients slows the decline of renal function (A randomized controlled trial) . Kidney Int . 2004;66:753–760
  26. Gerson A , Hwang W , Fiorenza J , et al.   Anemia and health-related quality of life in adolescents with chronic kidney disease . Am J Kidney Dis . 2004;44:1017–1023
  27. Montini G , Zacchello G , Baraldi E , et al.   Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis . J Pediatr . 1990;117:556–560
  28. Burke JR . Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure (Australian and New Zealand Paediatric Nephrology Association) . Pediatr Nephrol . 1995;9:558–561
  29. Jabs K , Alexander S , McCabe D , et al.   Primary results from the U.S. multicenter pediatric recombinant erythropoietin (EPO) study . J Am Soc Nephrol . 1994;5:546
  30. Jabs K . The effects of recombinant human erythropoietin on growth and nutritional status . Pediatr Nephrol . 1996;10:324–327
  31. Warady BA , Ho M . Morbidity and mortality in children with anemia at initiation of dialysis . Pediatr Nephrol . 2003;18:1055–1062
  32. Chavers BM , Li S , Collins AJ , et al.   Cardiovascular disease in pediatric chronic dialysis patients . Kidney Int . 2002;62:648–653
  33. Morris KP , Skinner JR , Hunter S , et al.   Cardiovascular abnormalities in end stage renal failure (The effect of anaemia or uraemia?) . Arch Dis Child . 1994;71:119–122
  34. Hutchinson FN , Jones WJ . A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease . Am J Kidney Dis . 1997;29:651–657
  35. Gokal R , Weatherall DJ , Bunch C . Iron induced increase in red cell size in haemodialysis patients . Q J Med . 1979;48:393–401
  36. Sieniawska M , Roszkowska-Blaim M . Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis . Pediatr Nephrol . 1997;11:628–630
  37. Ho M, Stablein DM: North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report. Rockville, MD, 2003
  38. Brandt JR , Avner ED , Hickman RO , et al.   Safety and efficacy of erythropoietin in children with chronic renal failure . Pediatr Nephrol . 1999;13:143–147
  39. Yalcinkaya F , Tumer N , Cakar N , et al.   Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis . Pediatr Nephrol . 1997;11:350–352
  40. Casadevall N , Nataf J , Viron B , et al.   Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin . N Engl J Med . 2002;346:469–475
  41. Asari A , Gokal R . Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis . J Am Soc Nephrol . 2004;15:2204–2207
  42. Nissenson AR , Swan SK , Lindberg JS , et al.   Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients . Am J Kidney Dis . 2002;40:110–118
  43. Vanrenterghem Y , Barany P , Mann JF , et al.   Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients . Kidney Int . 2002;62:2167–2175
  44. Walker R . Aranesp (darbepoetin alfa) administered at a reduced frequency of once every 4 weeks (Q4W) maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis . National Kidney Foundation Clinical Nephrology Meeting . 2002; April 17-21
  45. De Palo T , Giordano M , Palumbo F , et al.   Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis . Pediatr Nephrol . 2004;19:337–340
  46. Lerner G , Kale AS , Warady BA , et al.   Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease . Pediatr Nephrol . 2002;17:933–937
  47. Macdougall IC , Gray SJ , Elston O , et al.   Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients . J Am Soc Nephrol . 1999;10:2392–2395
  48. Evans JH , Brocklebank JT , Bowmer CJ , et al.   Pharmacokinetics of recombinant human erythropoietin in children with renal failure . Nephrol Dial Transplant . 1991;6:709–714
  49. Scott SD . Dose conversion from recombinant human erythropoietin to darbepoetin alfa (recommendations from clinical studies) . Pharmacotherapy . 2002;22:160S–165S
  50. Besarab A , Kaiser JW , Frinak S . A study of parenteral iron regimens in hemodialysis patients . Am J Kidney Dis . 1999;34:21–28
  51. Tenbrock K , Muller-Berghaus J , Michalk D , et al.   Intravenous iron treatment of renal anemia in children on hemodialysis . Pediatr Nephrol . 1999;13:580–582
  52. Greenbaum LA , Pan CG , Caley C , et al.   Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients . Pediatr Nephrol . 2000;14:908–911
  53. Campos A , Garin EH . Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO) . Clin Pediatr (Phila) . 1992;31:94–99
  54. Morris KP , Watson S , Reid MM , et al.   Assessing iron status in children with chronic renal failure on erythropoietin (Which measurements should we use?) . Pediatr Nephrol . 1994;8:51–56
  55. Fishbane S , Kowalski EA , Imbriano LJ , et al.   The evaluation of iron status in hemodialysis patients . J Am Soc Nephrol . 1996;7:2654–2657
  56. Schroder CH . The management of anemia in pediatric peritoneal dialysis patients . Pediatr Nephrol . 2003;18:805–809
  57. Gillespie RS , Wolf FM . Intravenous iron therapy in pediatric hemodialysis patients (A meta-analysis) . Pediatr Nephrol . 2004;19:662–666
  58. Yorgin PD , Belson A , Sarwal M , et al.   Sodium ferric gluconate therapy in renal transplant and renal failure patients . Pediatr Nephrol . 2000;15:171–175
  59. Morgan HE , Gautam M , Geary DF . Maintenance intravenous iron therapy in pediatric hemodialysis patients . Pediatr Nephrol . 2001;16:779–783
  60. Warady BA , Zobrist RH , Wu J , et al.   Sodium ferric gluconate complex therapy in anemic children on hemodialysis . Pediatr Nephrol . 2005;20:1320–1327
  61. Warady BA , Kausz A , Lerner G , et al.   Iron therapy in the pediatric hemodialysis population . Pediatr Nephrol . 2004;19:655–661
  62. Nissenson AR , Lindsay RM , Swan S , et al.   Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients (North American Clinical Trial) . Am J Kidney Dis . 1999;33:471–482
  63. Ruiz-Jaramillo Mde L , Guizar-Mendoza JM , Gutierrez-Navarro Mde J , et al.   Intermittent versus maintenance iron therapy in children on hemodialysis (A randomized study) . Pediatr Nephrol . 2004;19:77–81
  64. Folkert VW , Michael B , Agarwal R , et al.   Chronic use of sodium ferric gluconate complex in hemodialysis patients (Safety of higher-dose (> or =250 mg) administration) . Am J Kidney Dis . 2003;41:651–657
  65. Chandler G , Harchowal J , Macdougall IC . Intravenous iron sucrose (establishing a safe dose) . Am J Kidney Dis . 2001;38:988–991
  66. Fletes R , Lazarus JM , Gage J , et al.   Suspected iron dextran-related adverse drug events in hemodialysis patients . Am J Kidney Dis . 2001;37:743–749
  67. Coyne DW , Adkinson NF , Nissenson AR , et al.   Sodium ferric gluconate complex in hemodialysis patients (II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients) . Kidney Int . 2003;63:217–224
  68. Auerbach M , Chaudhry M , Goldman H , et al.   Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran (A double blind randomized trial) . J Lab Clin Med . 1998;131:257–260
  69. Pascual J , Teruel JL , Liano F , et al.   Serious adverse reactions after intravenous ferric gluconate . Nephrol Dial Transplant . 1992;7:271–272
  70. Hoigne R , Breymann C , Kunzi UP , et al.   Parenteral iron therapy (Problems and possible solutions) . Schweiz Med Wochenschr . 1998;128:528–535
  71. Hoen B , Paul-Dauphin A , Kessler M . Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients . Clin Nephrol . 2002;57:457–461
  72. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure . European best practice guidelines for the management of anaemia in patients with chronic renal failure . Nephrol Dial Transplant . 1999;14:S1–S50

PII: S1548-5595(05)00121-7

doi: 10.1053/j.ackd.2005.07.008

Advances in Chronic Kidney Disease
Volume 12, Issue 4 , Pages 385-396 , October 2005

Article Tools